Grade My Investments
HomeFree Stock Grades › AMRX

Amneal Pharmaceuticals, Inc. (AMRX) Stock Grade

AMRX · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$3.9B
P/E Ratio
54.8
Revenue Growth (YoY)
+8.1%
Net Margin
2.4%
Return on Equity
Dividend Yield
None

About Amneal Pharmaceuticals, Inc.'s fundamentals

Amneal Pharmaceuticals is a specialty and generic drug manufacturer with a market capitalization of $3.9 billion, currently generating 8.1% year-over-year revenue growth. The company operates on thin margins, with a net margin of just 2.4%, meaning only a small portion of each revenue dollar translates to profit. At a P/E ratio of 54.8, the stock is valued at a premium relative to current earnings, and the company does not currently pay a dividend to shareholders.

Track AMRX free — no credit card required. Live grade + monthly AI report →